MetaCap

OS Therapies (OSTX) vs Talphera (TLPH)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Talphera (TLPH) has outperformed OS Therapies (OSTX) over the past year, losing 41.4% versus a loss of 53.0%. OS Therapies is the larger company by market cap ($42.0 million vs $40.8 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

OSTX-53.04%TLPH-41.40%
+36%-15%-65%
Nov 21, 20251 yearNov 20, 2026
OSTX-79.92%TLPH-12.76%
+69%-10%-89%
Jul 29, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

OSTX versus TLPH key metrics
MetricOSTXTLPH
Share price$0.803$0.7852
Market cap$42.00M$40.80M
1-day change-2.12%+6.25%
YTD return-42.64%-31.12%
1-year return-53.04%-41.40%
5-year return—-93.96%
Forward P/E2.29—
EPS (TTM)$-1.08$-0.21
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$28.00K
Net income (latest FY)$-28.75M$-14.29M
Operating margin—-48157.14%
Net margin—-51035.71%
52-week high$2.25$1.57
52-week low$0.58$0.69
Distance from 52-week high-64.31%-49.99%
Analyst consensusstrong_buynone
Avg. price target upside+958.53%+298.62%
Average volume722.66K144.13K
Shares outstanding52.30M51.96M
Employees412
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • TLPH has outperformed OSTX by 11.6 percentage points over the past year.

About OS Therapies

OSTX stock →

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company's pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.

Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees

About Talphera

TLPH stock →

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit.

Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees

OSTX vs TLPH FAQ

Which is bigger, OS Therapies or Talphera?

OS Therapies (OSTX) is larger, with a market capitalization of $42.00M compared with $40.80M for Talphera (TLPH).

Which stock has performed better over the past year, OSTX or TLPH?

TLPH returned -41.40% over the past 12 months, compared with -53.04% for OSTX (price return, excluding dividends). Past performance does not predict future results.

Are OS Therapies and Talphera in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons